SOLID TUMOR

This study tests a new type of cancer vaccine made specifically for each person. The vaccine uses pieces of the patient's own tumor to teach their immune system to attack cancer cells. It is for people with solid tumors that have not spread or have spread to other parts of the bo…

This study tests a new drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab+ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…

This early-phase study tests a combination of low-dose radiation and a drug called 5-aminolevulinic acid (ALA) for people with advanced solid tumors that have stopped responding to standard treatments. ALA is thought to collect in cancer cells and make them more sensitive to radi…

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation and have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shrinks…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests a new drug called PRL3-zumab in adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug can slow tumor growth or shrink tumors. About 51 participants will receive the drug, and researchers will track how …

This early-phase study tests a new drug called BL-M02D1 in 22 adults with advanced digestive tract or other solid tumors that cannot be cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants…

This early-phase study tests a new treatment called BioTTT001, a modified virus designed to infect and kill cancer cells while boosting the immune system. It involves 12 adults with advanced solid tumors (like head and neck, colorectal, skin, or cervical cancer) who have not resp…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This study tests two experimental drugs, D-1553 and IN10018, together in people with advanced solid tumors that have a specific change in the KRAS gene (G12C). The goal is to find the safest and most effective dose and see if the combination can shrink tumors. About 140 adults wh…

This study tests a combination of two drugs—vorbipiprant and balstilimab—in people with advanced colorectal or other gastrointestinal cancers that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About…

This early-phase study tests a new oral drug combination (E7727 plus decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and to see if the drugs can slow tumor growth. Up to 35 parti…

This early-stage study tests a new drug, ASP4396, in adults with advanced solid tumors that have a specific change in the KRAS gene (G12D). The main goals are to find a safe dose and check for side effects. Participants receive the drug through a vein and are closely monitored fo…

This early-phase study tests a new oral drug called ABSK121-NX in about 169 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for any signs that th…

This study tests a drug called RP-3500 combined with radiation therapy for people with advanced solid tumors that have spread and have a specific gene change (ATM mutation). The goal is to find a safe dose and see if the combination can control tumor growth for at least 6 months.…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus …

This early-phase study tests a new oral drug, inavolisib, in people with advanced solid tumors or breast cancer that have a specific genetic change (PIK3CA mutation). The goal is to find safe doses and see how the drug works alone or combined with standard hormone therapies and t…

This early-phase study tests whether a drug called AZD1390, given together with a precise type of radiation (SBRT), is safe for people whose solid tumors have spread to other parts of the body. About 54 adults with metastatic cancer will receive increasing doses of the drug along…

This study tests an experimental pill (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug targets a DNA repair protein to try to shrink tumors. The trial will check safety, side effects, and how well the drug works alone …

This early-phase trial tests a new drug called BYON4228, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and see if tumors shrink. Only 7 participants are enro…

This early-phase study aims to find the safest dose of a three-drug combination (bortezomib, gemcitabine, and doxorubicin) for people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. About 80 participants will receive the treatment to see h…

This early-phase study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study includes people with several cancer types…

This study tests a combination of two drugs, SKB264 and pembrolizumab, in 240 adults with advanced solid tumors like cervical, ovarian, prostate, and bladder cancers. The goal is to see if the combo shrinks tumors and is safe. Participants must have a life expectancy of at least …

This study tests the safety of a drug called neratinib in children and teens whose solid tumors, brain tumors, lymphoma, or leukemia have returned or not responded to standard treatments. Researchers are looking for the best dose and watching for side effects. The goal is to see …

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the disease is …

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to target two immune checkpoints (PD-1 and CTLA-4) to help the immune system fight cancer. The…

This study tests a new drug (C019199) combined with an immunotherapy (sintilimab) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 155 adults w…

This early-phase study tests a new treatment called CATCH T cells for people with certain solid tumors (like liver cancer) that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells, adding special genes to help them recogniz…

This early-stage study tests an experimental pill called HBI-2376 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific gene changes (KRAS or EGFR mutations). The main goals are to find the safest dose and understand how the drug moves t…

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic mutation called KRAS G12C. The main goals are to find a safe dose and understand how the drug moves through the body. About 44 adults …

This early-stage trial tests a new treatment called BS006, a virus designed to infect and destroy cancer cells. It is given as a shot directly into the tumor for people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, fin…

This early-stage study tests a new drug called GS-4528, given alone or with another cancer drug, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 people will take part.

This study tests a personalized cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in 20 adults with solid tumors. The goal is to see if the combination is safe and helps control the cancer better than immunotherapy alone. Participan…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, skin, head/neck, or kidney cancer) that have not been cured by other treatments. The main goal is to check the drug's safety and find…

This study offers ongoing access to ibrutinib for 297 people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and still benefit from the drug but cannot get it commercially. Participants continue their current treatment while research…

This study was designed to test a new drug (IN10018) combined with chemotherapy and immunotherapy in people with advanced solid tumors, like lung cancer, that had stopped responding to earlier treatments. The goal was to see if the combination could shrink tumors or slow their gr…

This study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and doctors …

This study was designed to test an experimental treatment called GT316, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced gynecological tumors. The goal was to see if the therapy was safe and could shrink tumors. However, the study was wit…

This early-phase study tests a new drug called LY3200882 in 223 people with solid tumors. The main goal is to check the drug's safety and find the best dose. Researchers will also see if the drug helps shrink tumors or slow cancer growth.

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants re…

This early-stage trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack a protein called HLA-G found on certain solid tumors. The study includes 31 adults with advanced solid tumors that have …

This early-stage study tests a new drug called IDE397 in adults with advanced solid tumors that have not responded to standard treatments. The drug targets a specific genetic change (MTAP deletion) found in some cancers. The main goals are to check the drug's safety, find the bes…

This early-phase study tests the safety of adding the drug azeliragon to radiation therapy for adults whose cancer has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). About 21 participants with solid tumors or high-grade gliomas will receive the com…

This study tests whether benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The drug works by lowering eosinophil levels in the blood. About 51 adults with solid tumors or blood cancers who have moderate to severe skin reactions are…

This study was designed to track immune system recovery and test a pneumococcal vaccine (PCV-21) in people receiving CAR-T therapy for blood cancers or solid tumors. Participants would have had regular clinic visits and blood tests for up to 24 months. However, the study was with…

This study follows up to 5,000 children and teens who have had cancer or a stem cell transplant. Researchers collect health information over many years to learn about long-term side effects of treatment. The goal is to reduce future health problems and improve quality of life for…

This early-phase trial is testing whether atorvastatin, a widely used cholesterol medication, can reduce levels of a faulty protein called p53 in people with various cancers, including solid tumors and acute myeloid leukemia. About 50 participants will take the drug for 1 to 4 we…

This study looks at whether older adults with cancer (age 65+) can use computer surveys to report their health and daily living needs. Researchers tested two different computer methods to see if they are reliable and easy to use. The goal is to make it simpler for doctors to asse…

This study tests whether special ultrasound scans can detect early changes in tumor blood flow that show if immunotherapy is working. About 30 adults with solid tumors will get scans before and after 3 weeks of treatment. The goal is to see if these scans can predict tumor shrink…

This study tests a new full-digital PET scanner that watches proton beams as they travel through the body during cancer treatment. The goal is to see exactly where the beam delivers its dose, which could make proton therapy more precise. About 30 adults with solid tumors who are …